Related Experiment Video
Updated: Dec 27, 2025
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Genomic-guided precision therapy for soft tissue sarcoma
Hsing-Wu Chen1,2, Tom Wei-Wu Chen3
1Department of Oncology, National Taiwan University Hospital Yunlin Branch, Douliou, Yunlin, Taiwan.
Abstract:
Soft tissue sarcoma (STS), although heterogeneous in histopathology presentation, has mostly been treated with chemotherapy agents as one entity. Our understanding of crucial genomic alterations in different STS histologies and the advent of molecular-targeted agents have reshaped the treatment paradigm for advanced STS. Small-molecule inhibitors of c-KIT, plate-derived growth factor receptor alpha, c-MET, BRAF, anaplastic lymphoma kinase, ROS1 and colony-stimulating factor-1 receptor have been successfully validated in clinical studies to yield practice-changing results. Inhibitors of other novel genomic targets including mouse double minute 2 homolog, cyclin-dependent kinase 4/6, mitogen-activated protein kinase and epigenetic regulators are expected to be developed in the near future. Furthermore, with the advancement and accessibility of molecular diagnosis and next-generation sequencing, a genomic-based therapeutic approach should be widely applicable to advanced STS patients. This review will focus on the progress of genomic-guided therapy tailored to each molecular alteration of different STS histologies.
Insights
Genomic alterations in soft tissue sarcoma (STS) are driving new targeted therapies. Molecular diagnosis and next-generation sequencing enable personalized, genomic-guided treatment for advanced STS patients.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Soft tissue sarcoma (STS) is a heterogeneous cancer, historically treated uniformly with chemotherapy.
- Recent advances in understanding STS genomics have led to the development of targeted therapies.
- Molecularly targeted agents have begun to reshape treatment paradigms for advanced STS.
Purpose of the Study:
- To review the progress of genomic-guided therapy for soft tissue sarcoma.
- To highlight tailored treatments based on specific molecular alterations in different STS histologies.
- To discuss the impact of molecular diagnosis and next-generation sequencing on STS treatment.
Main Methods:
- Review of clinical studies validating small-molecule inhibitors.
- Analysis of genomic alterations in various STS histologies.
- Discussion of emerging therapeutic targets and epigenetic regulators.
Main Results:
- Small-molecule inhibitors targeting c-KIT, PDGFRA, c-MET, BRAF, ALK, ROS1, and CSF1R have shown practice-changing results.
- Several molecularly targeted agents have been successfully validated in clinical trials.
- Genomic-based therapeutic approaches are becoming increasingly applicable.
Conclusions:
- A genomic-guided therapeutic approach is crucial for advanced STS.
- Personalized medicine based on molecular alterations is transforming STS treatment.
- Future development of inhibitors for novel genomic targets will further advance STS care.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers